Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model

[1] Maas AI(2008)Moderate and severe traumatic brain injury in adults Lancet Neurol 7 728-741

[2] Stocchetti N(2010)The neurological outcome scale for traumatic brain injury (NOS-TBI): II. Reliability and convergent validity J Neurotrauma 27 991-997

[3] Bullock R(2009)Traumatic brain injury and long-term quality of life: findings from an Australian study J Neurotrauma 26 1623-1633

[4] McCauley SR(2010)Inflammatory neurodegeneration and mechanisms of microglial killing of neurons Mol Neurobiol 41 242-247

[5] Hawthorne G(2014)Innate immune activation in neurodegenerative disease Nat Rev Immunol 14 463-477

[6] Gruen RL(2012)Placebo-controlled trial of oral laquinimod for multiple sclerosis N Engl J Med 366 1000-1009

[7] Kaye AH(2014)Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage J Neurol Neurosurg Psychiatry 85 851-8

[8] Brown GC(2014)A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis J Neurol 261 773-783

[9] Neher JJ(2015)A phase II study of laquinimod in Crohn’s disease Gut 64 1227-1235

[10] Heneka MT(2014)Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells Arthritis Rheumatol 66 674-685

[1] Maas AI(2008)Moderate and severe traumatic brain injury in adults Lancet Neurol 7 728-741

[2] Stocchetti N(2010)The neurological outcome scale for traumatic brain injury (NOS-TBI): II. Reliability and convergent validity J Neurotrauma 27 991-997

[3] Bullock R(2009)Traumatic brain injury and long-term quality of life: findings from an Australian study J Neurotrauma 26 1623-1633

[4] McCauley SR(2010)Inflammatory neurodegeneration and mechanisms of microglial killing of neurons Mol Neurobiol 41 242-247

[5] Hawthorne G(2014)Innate immune activation in neurodegenerative disease Nat Rev Immunol 14 463-477

[6] Gruen RL(2012)Placebo-controlled trial of oral laquinimod for multiple sclerosis N Engl J Med 366 1000-1009

[7] Kaye AH(2014)Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage J Neurol Neurosurg Psychiatry 85 851-8

[8] Brown GC(2014)A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis J Neurol 261 773-783

[9] Neher JJ(2015)A phase II study of laquinimod in Crohn’s disease Gut 64 1227-1235

[10] Heneka MT(2014)Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells Arthritis Rheumatol 66 674-685